Vestor Capital LLC Makes New $224,000 Investment in Edwards Lifesciences Co. (NYSE:EW)

Vestor Capital LLC acquired a new stake in Edwards Lifesciences Co. (NYSE:EW) in the fourth quarter, HoldingsChannel reports. The firm acquired 2,940 shares of the medical research company’s stock, valued at approximately $224,000.

A number of other institutional investors have also modified their holdings of EW. Turtle Creek Wealth Advisors LLC purchased a new stake in Edwards Lifesciences in the 4th quarter valued at about $34,000. Operose Advisors LLC grew its holdings in Edwards Lifesciences by 247.0% in the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 452 shares during the period. SRS Capital Advisors Inc. raised its stake in Edwards Lifesciences by 292.6% during the third quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock worth $44,000 after purchasing an additional 474 shares during the period. NBC Securities Inc. acquired a new position in shares of Edwards Lifesciences in the 3rd quarter valued at $52,000. Finally, ORG Partners LLC purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at $66,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Wells Fargo & Company increased their target price on Edwards Lifesciences from $94.00 to $99.00 and gave the stock an “overweight” rating in a research report on Friday, April 26th. Barclays boosted their price objective on shares of Edwards Lifesciences from $100.00 to $101.00 and gave the stock an “overweight” rating in a research note on Tuesday. StockNews.com upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Monday, April 29th. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. Finally, Citigroup upped their price target on Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a report on Wednesday, April 3rd. One analyst has rated the stock with a sell rating, six have given a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus target price of $93.27.

Insiders Place Their Bets

In other Edwards Lifesciences news, SVP Robert W.A. Sellers sold 12,210 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $87.00, for a total value of $1,062,270.00. Following the completion of the transaction, the senior vice president now directly owns 13,087 shares in the company, valued at $1,138,569. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, Director Michael A. Mussallem sold 29,350 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $86.67, for a total value of $2,543,764.50. Following the completion of the transaction, the director now directly owns 4,486 shares of the company’s stock, valued at approximately $388,801.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Robert W.A. Sellers sold 12,210 shares of Edwards Lifesciences stock in a transaction on Monday, February 12th. The shares were sold at an average price of $87.00, for a total value of $1,062,270.00. Following the sale, the senior vice president now directly owns 13,087 shares in the company, valued at approximately $1,138,569. The disclosure for this sale can be found here. Over the last three months, insiders have sold 231,550 shares of company stock valued at $20,384,302. Company insiders own 1.27% of the company’s stock.

Edwards Lifesciences Stock Up 2.7 %

Edwards Lifesciences stock traded up $2.33 during midday trading on Thursday, hitting $87.42. The stock had a trading volume of 3,421,899 shares, compared to its average volume of 3,709,712. The business has a fifty day moving average price of $90.03 and a 200 day moving average price of $79.73. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12. The stock has a market cap of $52.68 billion, a P/E ratio of 37.68, a P/E/G ratio of 3.59 and a beta of 1.10. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The business had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. Research analysts predict that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.